Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:live_attenuated_varicella-zoster_virus
gptkb:Alphaherpesvirinae |
| gptkbp:age |
second dose at 4-6 years
first dose at 12-15 months |
| gptkbp:caused_by |
gptkb:varicella-zoster_virus
|
| gptkbp:community_impact |
significant reduction in cases
decreased hospitalizations reduction in healthcare costs |
| gptkbp:complications |
gptkb:healthcare_organization
gptkb:psychologist thrombocytopenia bacterial skin infections |
| gptkbp:current_use |
chickenpox
shingles |
| gptkbp:end_of_life |
higher in immunocompromised individuals
very low in healthy children |
| gptkbp:fledging_period |
1 to 2 days before rash appears
until all blisters have crusted over |
| gptkbp:healthcare |
mandatory vaccination in many countries
reduction in incidence due to vaccination |
| gptkbp:historical_event |
first described in the 9th century
vaccine developed in 1995 |
| https://www.w3.org/2000/01/rdf-schema#label |
varicella
|
| gptkbp:incubation_period |
10 to 21 days
|
| gptkbp:is_protected_by |
vaccination
|
| gptkbp:is_vulnerable_to |
gptkb:varicella_vaccine
live attenuated vaccine two doses recommended over 90% effective |
| gptkbp:risk_factor |
pregnant women
young children immunocompromised individuals unvaccinated individuals |
| gptkbp:side_effect |
fever
rare allergic reactions mild rash tenderness at injection site |
| gptkbp:social_responsibility |
seasonal outbreaks
clinical evaluation serological testing common in childhood |
| gptkbp:symptoms |
fatigue
headache muscle pain cough fever sore throat loss of appetite itchy rash |
| gptkbp:transmission |
airborne droplets
|
| gptkbp:treatment |
gptkb:acetaminophen
antihistamines supportive care antiviral medications calamine lotion |